ArticleOncoTargets and therapy2019

Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study.

Haimin Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.